4-吡啶甲醇盐酸盐 | 62302-28-7

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-吡啶甲醇盐酸盐
• 中文别名: 4-吡啶联苯胺盐酸盐
• 英文名称: 4-pyridinemethanol hydrochloride
• 英文别名: 4-pyridylcarbinol hydrochloride；[4]pyridyl-methanol; hydrochloride；[4]Pyridyl-methanol; Hydrochlorid；4-hydroxymethylpiperidinium chloride；4-hydroxymethylpyridine hydrochloride；Pyridin-4-ylmethanol hydrochloride；pyridin-4-ylmethanol;hydrochloride
• CAS: 62302-28-7
• 化学式: C₆H₇NO*ClH
• mdl: MFCD00230715
• 分子量: 145.589
• InChiKey: NKBJHERHVXOEIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.01
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  33.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-吡啶甲醇盐酸盐 在 氢溴酸 、 potassium carbonate 作用下， 反应 20.0h， 生成 N-methyl-N¹-<2-(4-pyridinylmethylthio)ethyl>urea
  参考文献：
  名称：

  El-Badry; Knaus, European Journal of Medicinal Chemistry, 1985, vol. 20, # 5, p. 403 - 407

  摘要：

  DOI：
• 作为产物：
  描述：

  4-吡啶甲醛 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 20.0 ℃ 、551.59 kPa 条件下， 反应 8.0h， 以98%的产率得到4-吡啶甲醇盐酸盐
  参考文献：
  名称：

  Controlling chemoselective transformations of 4-acylpyridines via a Pd–C catalytic hydrodechlorination–hydrogenation

  摘要：

  A novel Pd-C catalytic hydrodechlorination-hydrogenation was developed for a multi-step one-pot transformation of 4-acylpyridines. Under the selected conditions, 4-benzoylpyridines and 4-alkanoylpyridines were chemoselectively converted into the corresponding 4-benzylpiperidine hydrochlorides and alpha-alkyl-4-piperidinemethanol hydrochlorides, respectively. This catalytic method was performed simply by an addition of 1 equiv of CICH2CHCl2 to the conventional hydrogenation system and directly gave the crystalline piperidine hydrochlorides in practical quantitative yields. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.12.017

文献信息

• [EN] PYRROLO [1, 2-A] PYRAZINE DERIVATIVES AS VASOPRESSIN VIB RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLO [1, 2-A] PYRAZINE ANTAGONISTES DES RÉCEPTEURS V1B DE LA VASOPRESSINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009130231A1

  公开（公告）日：2009-10-29

  The present invention relates to novel compounds of formula (I) or salts thereof; wherein R is -X-[CH2]nCR4R5-Y; or a group G; R1 is H or C1 -C4 alkyl; R2 is aryl, heteroaryl or C3-C7 cycloalkyl, which may be substituted with one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, - CN; R3 is -CH2-C(=O)-NH-R6; X is -CR7R8-, -O-, -NR9-, -S-; Y is-NR10R11 R4 is H or C1 -C4 alkyl; R5 is H or C1 -C4 alkyl; R6 is C1-C6 alkyl, C3-C6 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R7 is H or C1 -C4 alkyl; R8 is H or C1 -C4 alkyl; R9 is H or C1 -C4 alkyl; R10 is H or C1-C4 alkyl, or together with R11 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR12; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R11 is H or C1 -C4 alkyl; R12 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; G is one of the groups selected from the list consisting of G1, G2, G3, G4, G5, G6, G7, G8, G9, G10, G11 and G12; R 13 is H or C1-C4 alkyl, or together with R14 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR24; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R14 R16 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R15, R 17 correspond to H or C1-C4 alkyl and may assume different meanings; R 18 is H or C1-C4 alkyl, or together with R17 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR25; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R19, R20, R21, R22, R23, R24, R25 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R26, R27, R28, R29 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; I, I' correspond to 1 or 2 and may assume different meanings; m, m', m", m"', mιv, mv correspond to 0, 1 or 2 and may assume different meanings; n is 1, 2 or 3; q is 1, 2 or 3; p, p', p", p'" correspond to 0, 1, 2 or 3 and may assume different meanings; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as antagonists of V1b receptors, e.g. to treat depression and anxiety.

  本发明涉及以下式（I）的新化合物或其盐；其中R为-X-[ ]nCR4R5-Y；或者为基团G；R1为H或C1-C4烷基；R2为芳基、杂环芳基或C3-C7环烷基，可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R3为-CH2-C（=O）-NH-R6；X为-CR7R8-、-O-、-NR9-、-S-；Y为-NR10R11；R4为H或C1-C4烷基；R5为H或C1-C4烷基；R6为C1-C6烷基、C3-C6环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R7为H或C1-C4烷基；R8为H或C1-C4烷基；R9为H或C1-C4烷基；R10为H或C1-C4烷基，或者与R11一起形成一个含有O、S和-NR12等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R11为H或C1-C4烷基；R12为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；G为从G1、G2、G3、G4、G5、G6、G7、G8、G9、G10、G11和G12的列表中选择的一种基团；R13为H或C1-C4烷基，或者与R14一起形成一个含有O、S和-NR24等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R14 R16为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R15、R17对应于H或C1-C4烷基，可能具有不同的含义；R18为H或C1-C4烷基，或者与R17一起形成一个含有O、S和-NR25等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R19、R20、R21、R22、R23、R24、R25为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R26、R27、R28、R29为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；I、I'对应于1或2，可能具有不同的含义；m、m'、m"、m"'、mιv、mv对应于0、1或2，可能具有不同的含义；n为1、2或3；q为1、2或3；p、p'、p"、p"'对应于0、1、2或3，可能具有不同的含义；它们的制备方法、在这些方法中使用的中间体、含有它们的药物组合物以及它们作为V1b受体拮抗剂在治疗中的用途，例如用于治疗抑郁症和焦虑症。
• [EN] PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS<br/>[FR] DÉRIVÉS DE PIRAZOLO [1, 5 -A] PYRAZINE, ANTAGONISTES DES RÉCEPTEURS V1B
  申请人：GLAXO GROUP LTD

  公开号：WO2009130232A1

  公开（公告）日：2009-10-29

  The present invention relates to novel compounds of formula (I) or salts thereof: wherein R is -X-[CH2]nCR4R5-Y; or a group G; G is one of the groups selected form the list consisting of G1, G2, G3, G4, G5, G6, G7, G8, G9, G10, G11 and G12, and the rest of the variables are as specified in the claims, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as antagonists of V1b receptors, e.g. to treat depression and anxiety.

  本发明涉及公式(I)的新化合物或其盐：其中R为-X-[CH2]nCR4R5-Y；或一个基团G；G是从G1、G2、G3、G4、G5、G6、G7、G8、G9、G10、G11和G12的列表中选择的基团之一，其余变量如索赔中所述，以及其制备方法、用于这些方法的中间体、含有它们的药物组合物以及它们作为V1b受体拮抗剂在治疗中的用途，例如用于治疗抑郁症和焦虑症。
• Hydroxymethylations of Aryl Halides by Pd-Catalyzed Cross-Couplings with (Benzoyloxy)methylzinc Iodide - Scope and Limitations of the Reaction
  作者：Michal Hocek、Zbyněk Hasník、Peter Šilhár

  DOI：10.1055/s-2008-1032084

  日期：——

  Palladium-catalyzed cross-coupling reactions of (benzoyloxymethyl)zinc iodide with diverse (het)aryl halides leading to (benzoyloxymethyl)(het)arenes were studied to define the scope of this reaction. It has been found that this reaction is only applicable for electron-deficient aryl halides and the most efficient it is for 2-halopyridines and 4-halopyrimidines. Deprotection of the intermediates gives

  研究了钯催化的（苯甲酰氧基甲基）碘化锌与多种（杂）芳基卤化物产生（苯甲酰氧基甲基）（杂）芳烃的交叉偶联反应，以确定该反应的范围。已发现该反应仅适用于缺电子的芳基卤化物，并且最有效的是用于 2-卤代吡啶和 4-卤代嘧啶。中间体的脱保护以高产率得到(羟甲基)吡啶和-嘧啶。
• Substituent effect of substrates on cucurbit[8]uril-catalytic oxidation of aryl alcohols
  作者：Hang Cong、Zhao-Jie Li、Yong-Huan Wang、Zhu Tao、Takehiko Yamato、Sai-Feng Xue、Gang Wei

  DOI：10.1016/j.molcata.2013.03.010

  日期：2013.8

  Based on the formation of the ternary host–guest inclusion complex between veratryl alcohol, o-iodoxybenzoic acid (IBX) and cucurbit[8]uril (Q[8]), the effect of substrate substituents on the IBX oxidation of aryl alcohols to the corresponding aldehyde subject to supramolecular catalysis by Q[8] in aqueous solvent is described. Aryl alcohols with different substituent effect on electron, for example, 2

  基于藜芦醇，邻碘氧基苯甲酸（IBX）和葫芦[8]尿素（Q [8]）之间的三元主客体包合配合物的形成，底物取代基对IBX氧化芳基醇至芳烃的影响描述了在水性溶剂中通过Q [8]超分子催化的相应醛。对电子具有不同取代基作用的芳基醇，例如2,3,4-甲氧基苄基醇和2,3,4-吡啶甲醇甲醇盐酸盐，已经过IBX流程在室温下，在不存在和存在Q [8]的情况下氧化。Q [8]的催化能力表明，取代基对芳醇的α-碳的电子效应对于Q [8]的催化氧化至关重要，并从机理上建议Q [8]的超分子催化作用是：对醇的贡献主要是对取代基的负诱导作用。
• 4-Phenoxymethyl-piperidines
  申请人：Boehringer Mannheim GmbH

  公开号：US04243807A1

  公开（公告）日：1981-01-06

  4-Phenoxymethyl-piperidines of the formula ##STR1## wherein R is hydrogen, halogen, nitro, lower alkyl or lower alkoxy, in the form of the free base or an acid addition salt, are provided and they are useful as intermediates in the production of anti-hypertensive agents through condensation with (a) propyl chloride and then with an adenine, or (b) a propyl indole.

  提供公式为##STR1##的4-苯氧甲基哌啶，其中R为氢、卤素、硝基、低烷基或低烷氧基，以自由碱或酸盐的形式提供，它们可用作抗高血压药物的中间体，通过与(a)丙基氯化物和腺嘌呤，或(b)丙基吲哚的缩合反应制备。